Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID)
Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Sponsor: Hospital Clinic of Barcelona
Terminated
lack of viability
Other terminated trials from Hospital Clinic of Barcelona
Listed as NCT04441385, this PHASE2 trial focuses on COVID-19 and remains terminated or withdrawn. Sponsored by Hospital Clinic of Barcelona, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Clinic of Barcelona
- Hospital Universitario Infanta Leonor
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .